Cheeper to import everything from paper to pork could 2020 be the end of tariffs and trade wars . And well be getting the inside track on the Wonderful World of welsh whiskey with a small dram of the good stuff. From trees to turkeys and even tinsel, the cost of christmas is rising we want to know how you save those pennies while keeping that festive cheer. Let us know just use the hashtag bbcworklife. Hello and welcome to worklife. Supermarket giant tesco has just suspended production of Charity Christmas cards at a factory in china after a six Year Old Girl found a message from workers inside one. The note was allegedly written by prisoners in shanghai claiming they were forced to work against our will. Tesco says its shocked by the report and would never allow prison labour in its supply chain. The supermarkets begun an investigation and says production at the factory in question has been suspended. Katie prescott reports. Ready . Uhhuh. Here we go. It was six year old schoolgirl Fl
Discussions examining threatening prosperity and exploring solutions. It is 100 clear to us that the cost of inaction is higher than the cost of action. When the rules are clear, we are going to follow those rules. Time is running out to address climate change, so i think it is right to hold our feet to the fire. Abigail this is all straight ahead on bloomberg best. Abigail hello, im abigail doolittle. Welcome to a special edition of bloomberg best with highlights from the Bloomberg Business global forum. This annual event brings together the worlds most influential leaders in business and government to address the most pressing global challenges and explore opportunities for solutions. The theme of this years conference was restoring global stability. The Prime Minister of india, narendra modi, delivered the keynote address and joined Michael Bloomberg on stage for a conversation. We believe the earth is our mother, and we do not have the right to exploit our earth. We are only have t
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So
We can see our Breast Cancer exceeds california and national rates, as well as our skin cancer and our Prostate Cancer are higher than those benchmarks as well. When we look in our nonmedicare population, on the top right, we see that we are lower than benchmark for breast and cervical and skin, but the prostate is higher than the california average in the Health Service system population. The next slide is doing the same sort of comparison here, but we are looking at it by cost. Instead of looking at it by prevalence, which is what the previous slide was doing. We have, again, Breast Cancer, leukemia, and lymphoma, all of those are our costliest cancers, and we are exceeding the california benchmark and exceeding the national rate. Moving to slide 11, here we are taking a look at it from a longer to do no approach trending three years. We have 2016 through 2018, and there is a Little Orange dash line in there that shows you a trendline of how is our prevalence going over the years. So